

Hanna Karvonen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6135331/publications.pdf>

Version: 2024-02-01

12
papers

256
citations

1163117

8
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

384
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular thermal shift assay (CETSA) for determining the drug binding affinity using Ba/F3 clones stably expressing receptor pseudokinases. <i>Methods in Enzymology</i> , 2022, 667, 339-363.	1.0	2
2	New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 276.	5.4	4
3	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
4	Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. <i>Cancers</i> , 2021, 13, 3727.	3.7	13
5	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. <i>Cell Death and Disease</i> , 2020, 11, 790.	6.3	38
6	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. <i>Molecular Cell</i> , 2020, 79, 390-405.e7.	9.7	56
7	Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. <i>Cells</i> , 2019, 8, 812.	4.1	30
8	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. <i>Oncogene</i> , 2019, 38, 3288-3300.	5.9	39
9	Interaction between <sc>ROR</sc>1 and Mu<sc>SK</sc> activation complex in myogenic cells. <i>FEBS Letters</i> , 2018, 592, 434-445.	2.8	8
10	Targeting Wnt signaling pseudokinases in hematological cancers. <i>European Journal of Haematology</i> , 2018, 101, 457-465.	2.2	13
11	Targeting ROR1 identifies new treatment strategies in hematological cancers. <i>Biochemical Society Transactions</i> , 2017, 45, 457-464.	3.4	28
12	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2257-2268.	5.2	25